Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 /
维生素D相关/核受体
代谢酶
/ VD/VDR / Paricalcitol/帕立骨化醇

Paricalcitol/帕立骨化醇 {[allProObj[0].p_purity_real_show]}

货号：A494988 同义名： 1α,25-Dihydroxy-19-nor-vitamin D2; Zemplar

Paricalcitol是一种维生素D类似物，作为维生素D受体激动剂，用于预防和治疗与慢性肾衰竭相关的继发性甲状旁腺功能亢进症。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Paricalcitol/帕立骨化醇 化学结构 CAS号：131918-61-1
Paricalcitol/帕立骨化醇 化学结构
CAS号：131918-61-1
Paricalcitol/帕立骨化醇 3D分子结构
CAS号：131918-61-1
Paricalcitol/帕立骨化醇 化学结构 CAS号：131918-61-1
Paricalcitol/帕立骨化醇 3D分子结构 CAS号：131918-61-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Paricalcitol/帕立骨化醇 纯度/质量文件 产品仅供科研

货号：A494988 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

Paricalcitol/帕立骨化醇 生物活性

描述 Paricalcitol is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.

Paricalcitol/帕立骨化醇 细胞实验

Cell Line
Concentration Treated Time Description References
N2a cells 15 nM 24 hours To evaluate the effect of Paricalcitol on Aβ42 oligomer-induced cell death. Results showed that Paricalcitol significantly reduced Aβ42 oligomer-induced mitochondrial 8-OHdG generation and increased cell viability. EBioMedicine. 2019 Jul;45:393-407.
N2a-sw cells 0-30 nM 24 hours To evaluate the effect of Paricalcitol on BACE1 expression in N2a-sw cells. Results showed that Paricalcitol dramatically downregulated BACE1 expression in a dose-dependent manner without altering the expression of APP, ADAM10, or PS1. EBioMedicine. 2019 Jul;45:393-407.
HK-2 cells 400 nM 24 hours To investigate the protective effect of Paricalcitol on Erastin-induced cell death, results showed that Paricalcitol pretreatment significantly alleviated Erastin-induced cell death Cell Death Dis. 2020 Jan 29;11(1):73.
HK-2 cells 400 nM 24 hours To investigate the protective effect of Paricalcitol on cisplatin-induced tubular cell injury, results showed that Paricalcitol pretreatment significantly reduced cisplatin-induced cell death Cell Death Dis. 2020 Jan 29;11(1):73.
HK-2 cells 0.5 ng/ml 3 days To evaluate the effect of Paricalcitol on high glucose-induced autophagy defects and inflammation. Results showed that Paricalcitol partially restored high glucose-induced autophagy defects and reduced the expression of inflammatory factors. Autophagy. 2022 Apr;18(4):877-890.
Human umbilical vein endothelial cells (HUVECs) 0.01, 0.1 or 1 µM 30 min pretreatment followed by 6 hours stimulation withours TNF-α To examine the effects of paricalcitol on TNF-α-induced expression of cell adhesion molecules. Results showed that paricalcitol suppressed the TNF-α-induced increase in ICAM-1, VCAM-1, and fractalkine expression in a dose-dependent manner. Int J Mol Med. 2016 Apr;37(4):1023-9.
5363 cells 300 nM 36 hours Evaluate the effect of PH combined with G on the growth inhibition of PDAC cells, results showed that GPH significantly inhibited PDAC cell growth. Cell Rep Med. 2025 Jan 21;6(1):101881.
PANC-1 cells 300 nM 36 hours Evaluate the effect of PH combined with G on the growth inhibition of PDAC cells, results showed that GPH significantly inhibited PDAC cell growth. Cell Rep Med. 2025 Jan 21;6(1):101881.
Mia PaCa-2 cells 300 nM 36 hours Evaluate the effect of PH combined with G on the growth inhibition of PDAC cells, results showed that GPH significantly inhibited PDAC cell growth. Cell Rep Med. 2025 Jan 21;6(1):101881.
KPC-Luc cells 300 nM 36 hours Evaluate the effect of PH combined with G on the growth inhibition of PDAC cells, results showed that GPH significantly inhibited PDAC cell growth. Cell Rep Med. 2025 Jan 21;6(1):101881.
HK-2 cells 0.1 µM 48 hours To evaluate the effect of PAR on HK-2 cell viability under high glucose conditions. PAR treatment significantly improved cell viability and reduced ROS generation. Adv Sci (Weinh). 2024 Mar;11(10):e2305563.
HK-2 cells 200 nM 72 hours Pretreatment with paricalcitol partially restored MAMs integrity and mitochondrial function via the Mfn2-MAMs-Fundc1 pathway. Redox Biol. 2024 Apr;70:103062.
Mouse kidney pericytes 20 ng/mL 90 min pretreatment followed by exposure to TGF-β1 or hypoxia for 48 hours To evaluate the protective effect of paricalcitol on TGF-β1 or hypoxia-induced pericyte injury. Results showed that paricalcitol reversed the upregulation of α-SMA, fibronectin, vimentin, and MMP-9 induced by TGF-β1 or hypoxia and restored PDGFRβ expression. Int J Mol Sci. 2021 Sep 9;22(18):9751.

Paricalcitol/帕立骨化醇 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Db/db mice Diabetic nephropathy model Intraperitoneal injection 0.1 μg/kg Once daily for 10 weeks To evaluate the effect of PAR on renal function in diabetic nephropathy mice. PAR treatment significantly attenuated kidney hypertrophy and albuminuria excretion, and improved blood glucose levels. Adv Sci (Weinh). 2024 Mar;11(10):e2305563.
C57BL/6 mice LPS-induced myocardial inflammation model Intraperitoneal injection 0.2 µg/kg Once daily for 5 days To investigate the effects of paricalcitol on LPS-induced myocardial inflammation. Results showed that paricalcitol pre-treatment significantly suppressed LPS-induced increases in myocardial ICAM-1, VCAM-1, and TNF-α expression and alleviated myocardial microvascular leakage. Int J Mol Med. 2016 Apr;37(4):1023-9.
C57BL/6 mice Cisplatin-induced acute kidney injury model Intraperitoneal injection 0.2 μg/kg Once daily for five consecutive days To investigate the protective effect of Paricalcitol on cisplatin-induced acute kidney injury, results showed that Paricalcitol pretreatment significantly improved renal function and attenuated tissue injury Cell Death Dis. 2020 Jan 29;11(1):73.
C57BL/6 mice Cisplatin-induced acute kidney injury model Injection 0.2 μg/kg Once daily for nine days Paricalcitol significantly improved renal function in mice, reduced inflammatory cell infiltration and mitochondrial damage in renal tissue, and suppressed oxidative stress and inflammation via the Nrf2/HO-1 signaling pathway. Int J Mol Sci. 2023 Jan 4;24(2):969
Rats Diabetic nephropathy model Intraperitoneal injection 0.25 mg/kg/day 5 times/week for 8 weeks To evaluate the renoprotective effects of Paricalcitol alone or in combination with omega-3 fatty acids against diabetic nephropathy. Results showed that Paricalcitol monotherapy improved glycemic control, lipid profile, and renal function, reduced renal oxidative stress and inflammation, while the combination therapy exhibited enhanced renoprotective effects. J Adv Res. 2021 Aug 18;38:119-129
C57BL/6J male mice PDAC orthotopic model Intravenous injection 0.3 mg/kg Twice weekly for 14 days Evaluate the effect of GPH on tumor growth in PDAC orthotopic models, results showed that GPH significantly reduced tumor growth and improved survival. Cell Rep Med. 2025 Jan 21;6(1):101881.
Mice Ischemia-reperfusion induced acute kidney injury model Intraperitoneal injection 0.3 μg/kg Injected one time at 1 day before the injury Paricalcitol, as a clinically used activator for PGE2 synthesis, alleviated injury-induced AKI/AKI-CKD stages and eliminated the worst outcomes observed in ApelaKsp KO mice when used alone or in combination with nor-NOHA. Theranostics. 2023 Jun 4;13(10):3387-3401
Mice Streptozotocin-induced diabetic model Intraperitoneal injection 0.4 µg/kg Three times a week for 12 weeks To evaluate the effect of Paricalcitol on the progression of diabetic nephropathy. Results showed that Paricalcitol alleviated STZ-induced albuminuria, renal tubule injury, and inflammation, and partially restored autophagy defects. Autophagy. 2022 Apr;18(4):877-890.
APP/PS1 transgenic mice Alzheimer's disease model Intraperitoneal injection 200 ng/kg Once every two days for 15 weeks To evaluate the effect of Paricalcitol on cognitive ability and Aβ generation in APP/PS1 mice. Results showed that long-term Paricalcitol treatment significantly reduced Aβ generation and neuronal loss and improved cognitive ability in mice. EBioMedicine. 2019 Jul;45:393-407.
Sprague-Dawley rats Adriamycin-induced nephropathy model Subcutaneous osmotic pump 6 ng/day Once daily for 27 days To evaluate the effect of paricalcitol on renal endothelial toxicity in a model of CKD induced by ADR in rats and explore mechanisms involved in endothelial cell maintenance. Results showed that paricalcitol improved renal function and structure through antiproteinuric effects and glomerular and tubular protection. Nutrients. 2022 Dec 14;14(24):5316
Rats Endothelial denudation-induced intimal hyperplasia Intraperitoneal 750 ng/kg Every other day for 2 weeks Paricalcitol significantly suppressed the stress response and inflammatory features induced by endothelial injury but had a limited impact on intimal hyperplasia and luminal stenosis. Int J Mol Sci. 2024 Apr 28;25(9):4814

Paricalcitol/帕立骨化醇 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01204528 Chronic Kidney Disease Phase 2 Phase 3 Completed - Sweden ... 展开 >> Karolinska Institute at Danderyd University Hospital Danderyd, Stockholm, Sweden, 18288 收起 <<
NCT02018133 CKD Stage 3/4 Phase 3 Completed - United States, Illinois ... 展开 >> University of Illinois at Chicago Chicago, Illinois, United States, 60612 收起 <<
NCT03138720 Resectable Pancreatic Cancer ... 展开 >> Unresectable Pancreatic Cancer Pancreatic Adenocarcinoma 收起 << Phase 2 Recruiting March 1, 2020 United States, Arizona ... 展开 >> HonorHealth Research Institute Recruiting Scottsdale, Arizona, United States, 85258 Contact: Joyce Schaffer, MSN, AOCNS    480-323-1339 ext option #2    Joyce.Schaffer@HonorHealth.com    Principal Investigator: Erkut Borazanci, MD 收起 <<

Paricalcitol/帕立骨化醇 参考文献

[1]Suarez-Martinez E, Husain K, et al. Adiponectin expression and the cardioprotective role of the vitamin D receptor activator paricalcitol and the angiotensin converting enzyme inhibitor enalapril in ApoE-deficient mice. Ther Adv Cardiovasc Dis. 2014 Dec;8(6):224-36.

[2]Halder SK, Sharan C, et al. Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids. Reprod Sci. 2014 Sep;21(9):1108-19.

Paricalcitol/帕立骨化醇 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

12.00mL

2.40mL

1.20mL

24.00mL

4.80mL

2.40mL

Paricalcitol/帕立骨化醇 技术信息

CAS号131918-61-1
分子式C27H44O3
分子量 416.64
SMILES Code C[C@]([C@]([C@H](C)/C=C/[C@H](C)C(C)(C)O)([H])CC1)(CCC/2)[C@]1([H])C2=C\C=C3C[C@@H](O)C[C@H](O)C/3
MDL No. MFCD08067734
别名 1α,25-Dihydroxy-19-nor-vitamin D2; Zemplar; paricalcitol-d6; Abbott brand of paricalcitol; Paracalcin; 19-Nor-1alpha,25-dihydroxyvitamin D2; Compound 49510; 19-nor-1,25-Dihydroxyvitamin D2
运输蓝冰
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, store in freezer, under -20°C
溶解方案

DMSO: 105 mg/mL(252.02 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

无水乙醇: 12.5 mg/mL(30 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一

Tags: Paricalcitol | 131918-61-1 | VD/VDR | Vitamin D | Vitamin D Receptor Agonist | Vitamin D Related/Nuclear Receptor | VD/VDR | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Paricalcitol/帕立骨化醇 纯度/质量文件 | Paricalcitol/帕立骨化醇 生物活性 | Paricalcitol/帕立骨化醇 临床数据 | Paricalcitol/帕立骨化醇 参考文献 | Paricalcitol/帕立骨化醇 实验方案 | Paricalcitol/帕立骨化醇 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z